Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre,open-label,single-arm,phase 2/3 trial |
| |
| Affiliation: | 1. Ministry of Health, Kinshasa, Democratic Republic of the Congo;2. Drugs for Neglected Diseases initiative, Kinshasa, Democratic Republic of the Congo;3. Drugs for Neglected Diseases initiative, Geneva, Switzerland;4. Dipumba Hospital (MIBA), Mbuji-Mayi, Democratic Republic of the Congo;5. Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea;6. Swiss Tropical and Public Health Institute, Allschwil, Switzerland;7. University of Basel, Basel, Switzerland;8. Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo;9. Bandundu Hospital, Vanga, Democratic Republic of the Congo;10. HAT treatment centre, Dubreka, Guinea;11. Masi Manimba Hospital, Masi-Manimba, Democratic Republic of the Congo;12. Katanda Hospital, Mbuji-Mayi, Democratic Republic of the Congo;13. Isangi Hospital, Isangi, Democratic Republic of the Congo;14. Bagata Hospital, Bagata, Democratic Republic of the Congo;15. Ngandajika Hospital, Kasaï Oriental, Democratic Republic of the Congo;p. Kwamouth Hospital, Kwamouth, Democratic Republic of the Congo;q. Bolobo Hospital, Bolobo, Democratic Republic of the Congo;r. Roi Baudoin Hospital, Kinshasa, Democratic Republic of the Congo;s. Nkara Hospital, Nkara, Democratic Republic of the Congo;t. Kimpese Hospital, Kimpese, Democratic Republic of the Congo;u. Bruno Scherrer Conseil, Saint Arnoult en Yvelines, France |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
